Form 4: Benitec CFO Acquires 200,000 Stock Options

Benitec Biopharma's Chief Financial Officer and Director, Megan Boston, acquired 200,000 stock options with an exercise price of $13.53, vesting quarterly from March 2026.

Summary

• Megan Boston, Chief Financial Officer and Director of Benitec Biopharma Inc. (BNTC), reported the acquisition of 200,000 derivative securities in the form of stock options.
• The options have an exercise price of $13.53 per share.
• The transaction date for the acquisition was November 18, 2025.
• The options will expire on November 18, 2035.
• Vesting of these stock options will occur in 16 substantially equal quarterly installments, commencing on March 31, 2026.
• Following this transaction, Megan Boston beneficially owns 200,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is generally viewed as a positive for aligning management incentives with shareholder interests, though it doesn't reflect operational or financial performance directly.

Positives

• The grant of 200,000 stock options to a key executive like the CFO and Director, Megan Boston, aligns her interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule over several years (starting March 2026) suggests a commitment to retaining key management and driving sustained growth.

Negatives

• No direct negatives are apparent from this specific Form 4 filing, which solely reports an insider transaction.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The grant of stock options with a long-term vesting schedule and expiration date indicates an expectation of continued service from the CFO and a focus on long-term value creation for the company.

Industry Context

Executive stock option grants are a common form of compensation in the biotechnology and pharmaceutical industries, used to attract, retain, and incentivize key talent by linking their financial success to the company's stock performance. This grant is consistent with typical executive compensation practices aimed at aligning management and shareholder interests.

Stakeholder Impact

• Shareholders: The grant of stock options to the CFO aligns her financial incentives with the long-term performance of the company's stock, potentially benefiting shareholders if the stock price increases.
• Employees: This compensation structure for a senior executive may set a precedent or reflect the company's overall approach to incentivizing its leadership team.

Next Steps

• The stock options will begin vesting in quarterly installments starting March 31, 2026.

Key Dates

Keywords

Benitec Biopharma, BNTC, stock options, executive compensation, insider transaction, Form 4, Megan Boston, CFO, director, equity grant